Research · 11 min read
GLP-1s, Insulin, and Sulfonylureas: The One Warning Every Label Carries
These drugs disagree with each other about a lot. On this they agree completely: adding a GLP-1 to insulin or a sulfonylurea raises the risk of low blood sugar, including the severe kind. It is the one interaction a rushed intake form is most likely to miss.
Key takeaways
- All five labels read for this carry both a hypoglycemia warning and a drug-interactions subsection for insulin or an insulin secretagogue.
- A GLP-1 stimulates insulin release when glucose is elevated; a sulfonylurea pushes insulin out regardless, which is why the combination is the concern.
- The labels instruct prescribers to consider reducing the dose of an existing insulin or secretagogue — an instruction that depends on knowing your full medication list.
- They also place a duty on the prescriber to inform patients of the signs and symptoms of low blood sugar.
- Foundayo's label reports hypoglycemia in seven percent of patients taking it with a sulfonylurea versus half a percent without one, in the same trial.
- The Wegovy label separately states that adding it for patients already treated with insulin has not been evaluated — unstudied, rather than cleared.
- Slowed stomach emptying runs the other way too, changing absorption of swallowed drugs such as warfarin and levothyroxine.
- An online intake knows only what you typed, so disclosing every blood sugar medication by name is the step the whole warning depends on.
Answer first: five labels, one shared warning
Five FDA-approved labels were read for this: Wegovy, Ozempic injection, the shared Rybelsus and Ozempic tablet label, Zepbound, and Foundayo. Every one of the five carries a hypoglycemia warning, and every one carries a separate drug-interactions subsection about insulin or an insulin secretagogue.
The labels differ on plenty of other things. They differ on oral contraceptives, on approved uses, on food conditions, on which liver enzymes matter. On this one they say nearly the same sentence.
Used on its own in someone without diabetes, a GLP-1 is not the usual cause of dangerous low blood sugar. The warning is about the combination, and the combination is common — plenty of people arriving at a weight program are already on something for blood sugar.
So the single most useful thing you can do before starting is make sure whoever prescribes knows every diabetes medication you take, by name. That is the whole point of this page.
Why the combination is the risky part
A GLP-1 stimulates insulin release in the presence of elevated blood glucose. The labels put it in almost those words. That conditional clause is the safety feature: when glucose is not high, the push is not there.
A sulfonylurea does not work that way. It is an insulin secretagogue, which means it prompts the pancreas to release insulin regardless of what your glucose is doing at that moment. Glipizide, glyburide, and glimepiride are the ones most people are actually holding.
Injected insulin is even less conditional. It is a fixed amount, already decided, already administered.
Stack a glucose-lowering drug on top of either of those and the floor moves. Nothing about the GLP-1 has changed; what changed is that it was added to something that lowers blood sugar without asking.
There is a second mechanism worth knowing about. These drugs slow the stomach, which changes the timing of how food arrives — and timing is exactly what a dose of insulin or a sulfonylurea was matched against.
What the labels actually say
The highlights section of each label is the compressed version, and the wording is close to identical across manufacturers. Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia.
Each one then adds the same two instructions, both aimed at prescribers rather than at you. Reducing the dose of the insulin or the secretagogue may be necessary. And: inform all patients of the risk of hypoglycemia, and educate them on the signs and symptoms.
That second instruction is a duty placed on the person who prescribes. If nobody has walked you through what low blood sugar feels like and what to do about it, something the label asked for has not happened yet.
Foundayo's label puts a number on the difference. In one trial, hypoglycemia was reported in seven percent of patients taking orforglipron together with a sulfonylurea, compared with half a percent of those not taking one.
Read those two figures against each other rather than on their own. It is the same drug in the same trial, and the sulfonylurea is the variable.
The tirzepatide and semaglutide labels describe the same direction of effect in their own trials. None of these numbers predicts anything about you; they establish that the interaction is real and measured rather than theoretical.
The sentence in the Wegovy label worth pausing on
One line does something the others do not. The Wegovy label states that the addition of Wegovy in patients treated with insulin has not been evaluated.
That is not a warning that something bad happens. It is a statement that the study was not done, which is a different and in some ways more useful thing to know.
The distinction matters because of how these conversations usually go. "There is no evidence of a problem" and "the combination has not been studied" sound similar in a chat window and mean opposite things about how much anyone knows.
If you are on insulin and considering this product, that sentence belongs in the conversation. Ask directly what is known about the combination for someone in your situation, and treat a confident answer as something to check rather than something settled.
Why this lands differently when you sign up online
A traditional prescriber has your chart. They can see the sulfonylurea you were started on years ago, the insulin your endocrinologist adjusts, and the last set of labs.
An online intake knows what you typed into it. That is the honest description of the difference, and it is not a criticism of any particular program — it is a description of the instrument.
The labels assume a prescriber who knows your full medication list, because both of their instructions depend on it. Considering whether another drug's dose needs to come down is impossible if that drug was never disclosed.
This is also why intake forms ask what they ask. A question about diabetes medications is not paperwork; it is the step that this warning exists to trigger.
So answer those questions completely, including the drug you have been on so long you forget to list it. If the form has nowhere to put something, put it in the free-text box, and say it again at any point where a person is reachable.
It is also worth knowing which prescriber is yours, and how you reach them between visits, before you need to.
The other direction: what a slowed stomach does to swallowed drugs
The same labels carry a second interaction subsection, and it points the other way. Delayed gastric emptying can change how any oral medication is absorbed.
Some are specific about where that matters most. The tirzepatide label names warfarin as an example of a drug with a narrow therapeutic index that warrants monitoring. The semaglutide tablet label reports that levothyroxine exposure rose in a drug interaction study.
"Narrow therapeutic index" is the phrase to remember. It describes a drug where the gap between too little and too much is small, so a shift in absorption is not academic.
None of that means those combinations are off limits. The labels ask for monitoring, not avoidance, and monitoring is something a prescriber arranges.
Oral hormonal contraceptives are the one case where the labels genuinely disagree with each other, and that difference is covered separately.
What to establish, in order
Write down every medication you take for blood sugar, by brand and generic name, before any intake form. Include anything you stopped recently, and anything another prescriber manages.
Confirm the person prescribing has that list and has acknowledged it. An intake field you filled in is not the same as a prescriber who has read it.
Ask what the plan is for the medications you are already on, since the labels raise the question directly and the answer belongs to a prescriber rather than to a form.
Ask to be told the signs and symptoms of low blood sugar and what to do about them. The labels place that duty on the prescriber, so asking for it is asking for something you are owed.
Then ask how to reach someone if something happens between appointments, and get the answer before you need it. That question separates a program with a clinician behind it from one with a checkout page.
Sources
- WEGOVY (semaglutide) injection, solution; WEGOVY (semaglutide) tablet — full prescribing informationThe hypoglycemia warning and the insulin and secretagogue interaction subsection. Also the statement that adding the product for patients already treated with insulin has not been evaluated, and the oral-medication absorption warning.
- OZEMPIC (semaglutide) injection, solution — full prescribing informationThe wording that semaglutide stimulates insulin release in the presence of elevated blood glucose, and the instruction that prescribers consider reducing a concomitant insulin or secretagogue dose.
- OZEMPIC (oral semaglutide) tablet; RYBELSUS (oral semaglutide) tablet — full prescribing informationThat the oral form carries the same hypoglycemia and secretagogue warnings as the injection, and the reported increase in levothyroxine exposure in a drug interaction study.
- ZEPBOUND (tirzepatide) injection, solution — full prescribing informationThat a tirzepatide label carries the same hypoglycemia and secretagogue warnings, and names warfarin as a narrow therapeutic index drug warranting monitoring.
- FOUNDAYO (orforglipron) tablet, film coated — full prescribing informationThe reported hypoglycemia rates with and without a concomitant sulfonylurea in the same trial, and that a non-peptide oral GLP-1 carries the same combination warning.
Frequently asked questions
Can a GLP-1 cause low blood sugar on its own?
The labels say these drugs lower blood glucose and can cause hypoglycemia, so it is not impossible. But the warnings concentrate on the combination for a reason: a GLP-1 stimulates insulin release in the presence of elevated blood glucose, and that conditional clause is doing the protective work. The risk climbs when it is added to something that lowers blood sugar unconditionally — insulin, or an insulin secretagogue such as a sulfonylurea. If you take neither, the labeled concern is smaller. That is still a conversation for your prescriber rather than a conclusion to reach from an article.
What is an insulin secretagogue?
It is a drug that prompts the pancreas to release insulin. The labels use the term and then give sulfonylureas as the example, which is the class most people are actually taking — glipizide, glyburide, and glimepiride are common ones. The important part is the difference in behavior. A GLP-1 stimulates insulin release when glucose is elevated; a secretagogue pushes insulin out regardless of what your glucose is doing at that moment. Combining a conditional effect with an unconditional one is what the warning is about.
Do I have to stop my diabetes medication to start a GLP-1?
That is a prescriber's decision and not something to act on from a web page. What the labels say is that reducing the dose of a concomitantly administered insulin or insulin secretagogue may be necessary, and that instruction is addressed to whoever is prescribing. Do not change, skip, or adjust anything on your own. What you can do is make sure the prescriber has your complete medication list and has told you what the plan is for each item on it. If nobody has raised the question with you, raise it yourself.
Does this apply to compounded versions too?
The molecule behaves the way the molecule behaves, so a compounded preparation containing the same active ingredient raises the same pharmacological question. What differs is the paperwork around it. An FDA-approved product arrives with an approved label and a Medication Guide that state the warning in fixed words; a compounded preparation is not an FDA-approved product and does not carry an approved label. That makes the prescriber's knowledge of your medication list more load-bearing, not less. Ask what documentation comes with the product and what it says about this interaction.
The Wegovy label says the combination with insulin has not been evaluated. Is that a warning?
It is a statement about what was studied, which is a different thing and worth reading precisely. The label carries a hypoglycemia warning and a drug-interactions subsection covering insulin and secretagogues, and separately notes that the addition of Wegovy in patients already treated with insulin has not been evaluated. Absence of a study is not evidence of safety and it is not evidence of harm. It means the honest answer for that specific combination is that less is known. If you are on insulin, that sentence is worth putting in front of your prescriber directly.
Why does the intake form ask about my other medications so many times?
Because two labeled instructions depend on the answer. One asks the prescriber to consider whether another drug's dose needs to come down; the other asks the prescriber to educate you about the signs and symptoms of low blood sugar. Neither is possible if a medication was never disclosed. An online intake knows only what you typed, so the form is carrying weight that a chart would otherwise carry. Answer completely, including anything you have taken so long you no longer think of it as a medication.